BMRN up +3.29% percent right now. $BMRN High is at 88.23

New Post Public Reply Private Reply Replies (0) Message Board

Nov 10, 2014 at 12:41 PM

BMRN up +3.29% percent right now. $BMRN High is at 88.23 and the Low 85.78 with current volume of 633,615.

Recent News posted below.

BMRN Biomarin Pharmaceutical Inc Recent Headline News

Upgrade Alert for BioMarin Pharmaceutical (BMRN)
Comtex SmarTrend(R) - Mon Nov 10, 7:56AM CST
BioMarin Pharmaceutical (NASDAQ:BMRN) was upgraded from Neutral to Buy at Goldman Sachs today. The stock closed yesterday at $83.91 on volume of 727,000 shares, below average daily volume of 1.2 million. In the past 52 weeks, shares of BioMarin Pharmaceutical have traded between a low of $55.04 and a high of $86.80 and closed yesterday at $83.91, which is 52% above that low price. In the last five trading sessions, the 50-day moving average (MA) has climbed 1.8% while the 200-day MA has risen 0.4%.
BMRN: 86.93 (+3.02)

Shares of BMRN Up 13.7% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Wed Nov 05, 10:01AM CST
SmarTrend identified an Uptrend for BioMarin Pharmaceutical (NASDAQ:BMRN) on October 21st, 2014 at $73.58. In approximately 2 weeks, BioMarin Pharmaceutical has returned 13.66% as of today's recent price of $83.63.
BMRN: 86.93 (+3.02)

Is This Trend Making Gilead Sciences, Inc. Worry?
Todd Campbell, The Motley Fool - Motley Fool - Wed Nov 05, 9:40AM CST
Source: Gilead Sciences via Google Maps If you're sick, you expect your doctor to prescribe the appropriate treatment -- and if that treatment is a revolutionary medicine like Gilead 's Harvoni, you expect that your insurer will pay for it....
MNK: 92.45 (+1.39), VRTX: 116.15 (+0.22), BMRN: 86.93 (+3.02), GILD: 107.50 (+1.05), ALXN: 193.69 (-0.12)

Why BioMarin Pharmaceutical Inc. Roared 14% Higher in October
Sean Williams, The Motley Fool - Motley Fool - Wed Nov 05, 9:01AM CST
BMRN data by YCharts What: Shares of BioMarin Pharmaceutical , a biopharmaceutical company focused on developing therapies to treat rare and ultra-rare diseases and disorders, roared higher by 14% in October, based on data from S&P...
BMRN: 86.93 (+3.02)

Jean-Jacques Bienaime, CEO of BioMarin, to Present at the Credit Suisse 2014 Healthcare Conference
GlobeNewswire - Tue Nov 04, 7:00AM CST
BioMarin Pharmaceutical Inc. (Nasdaq:BMRN), today announced that Jean-Jacques Bienaime, Chief Executive Officer at BioMarin, will present at the Credit Suisse 2014 Healthcare Conference on Tuesday, November 11, 2014 at 1:30pm MT.
BMRN: 86.93 (+3.02)

Cramer Sees HP Entering Sector as Trouble for 3-D Printing Stocks
at The Street - Mon Nov 03, 10:57AM CST
Even though HP won't start shipping its 3-D printing machines in bulk until 2016, it could be a problem for other 3-D printing companies.
BMRN: 86.93 (+3.02), ISIS: 46.18 (+1.59), SGEN: 35.55 (-0.50), GILD: 107.50 (+1.05), SSYS: 103.96 (+0.89), HP: 86.16 (-0.54), REGN: 382.94 (+5.10), CELG: 107.49 (+1.04)

Quarterly Earnings Releases and Recognitions - Research Reports on GlaxoSmithKline, IDEXX, BioMarin, GE and Lockheed Martin
PR Newswire - Wed Oct 29, 8:30AM CDT
Today, Analysts Review released its research reports regarding GlaxoSmithKline plc (NYSE: GSK), IDEXX Laboratories, Inc. (NASDAQ: IDXX), BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), General Electric Company (NYSE: GE) and Lockheed Martin Corporation (NYSE: LMT). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7542-100free.
LMT: 186.97 (+0.82), GE: 26.48 (+0.07), BMRN: 86.93 (+3.02), IDXX: 146.82 (+1.66), GSK: 45.17 (+0.26), NVS: 92.41 (+0.65)

Can the Rally in BioMarin Pharmaceutical (BMRN) Shares Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Oct 29, 7:54AM CDT
Can the Rally in BioMarin Pharmaceutical (BMRN) Shares Continue?
BMRN: 86.93 (+3.02)

BioMarin Pharmaceutical (BMRN) Jumps: Stock Rises 8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Oct 27, 7:51AM CDT
BioMarin Pharmaceutical Inc. (BMRN) was a big mover last session, as its shares rose a little over 8% on the day.
MDVN: 110.24 (-2.53), MACK: 8.56 (-0.14), BMRN: 86.93 (+3.02), ILMN: 188.87 (+2.52)

The 5 Most Expensive Drugs in the World
Sean Williams, The Motley Fool - Motley Fool - Sun Oct 26, 11:21AM CDT
Source: StockMonkeys.com via Flickr . Whether you're prepared for it or not, prescription drug prices remain on the rise within the United States. Overall medical cost inflation may be at a multi-decade low in the U.S., but that doesn't seem to...
MNK: 92.45 (+1.39), VRTX: 116.15 (+0.22), BMRN: 86.93 (+3.02), SHPG: 200.96 (+2.38), ALXN: 193.69 (-0.12)

After Yesterday's Rally of 8.03% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Fri Oct 24, 4:47PM CDT
BioMarin Pharmaceutical (NASDAQ:BMRN) traded in a range yesterday that spanned from a low of $75.40 to a high of $81.83. Yesterday, the shares gained 8.0%, which took the trading range above the 3-day high of $75.86 on volume of 2.4 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
BMRN: 86.93 (+3.02)

BioMarin Q3 Loss Narrower than Expected, View Raised - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Oct 24, 12:12PM CDT
BioMarin Pharmaceutical Inc. (BMRN) reported a narrower-than-expected third-quarter 2014 loss of 16 cents per share.
MDVN: 110.24 (-2.53), BMRN: 86.93 (+3.02), ILMN: 188.87 (+2.52), SNY: 46.29 (+0.60)

BioMarin Pharmaceutical Inc. Earnings: Striving to Be a Blockbuster Company
Brian Orelli, The Motley Fool - Motley Fool - Thu Oct 23, 7:38PM CDT
Every biotech dreams of having a blockbuster drug with annual sales higher than $1 billion. But ultra-orphan-drugmaker BioMarin Pharmaceuticals has a more realistic short-term goal: have $1 billion in sales for biotech's basket of five drugs. ...
BMRN: 86.93 (+3.02), SNY: 46.29 (+0.60)

BioMarin Announces Third Quarter 2014 Financial Results
GlobeNewswire - Thu Oct 23, 3:02PM CDT
- VIMIZIM Sales Top $25 million in Second Full Quarter of Sales
BMRN: 86.93 (+3.02)

Will BioMarin (BMRN) Disappoint This Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Oct 21, 4:30PM CDT
BioMarin is scheduled to report third-quarter 2014 results on Oct 23.
VRTX: 116.07 (+0.14), BMRN: 86.93 (+3.02), LGND: 53.72 (-0.22), TEVA: 58.05 (+0.35)

Some Potential Targets for Shire to Buy With $1.6B in Free Money
at The Street - Tue Oct 21, 8:29AM CDT
Shire isn't obligated to spend AbbVie's money, but it's no fun speculating about earned interest. Which drug companies might be takeout targets for Shire?
BMRN: 86.93 (+3.02), ALNY: 98.92 (+3.08), SRPT: 16.10 (-0.02), SHPG: 200.96 (+2.38), NPSP: 26.96 (-0.53)

Analyst Scanner on Biotech Equities - Amgen, Exelixis, Regeneron Pharma, Lexicon Pharma, and BioMarin Pharma
PR Newswire - Mon Oct 20, 8:00AM CDT
Investor-Edge has initiated coverage on the following equities: Amgen Inc. (NASDAQ: AMGN), Exelixis Inc. (NASDAQ: EXEL), Regeneron Pharmaceuticals Inc. (NASDAQ: REGN), Lexicon Pharmaceuticals Inc. (NASDAQ: LXRX), and BioMarin Pharmaceutical Inc. (NASDAQ: BMRN). Free research on these five companies can be accessed at: http://investor-edge.com/register. The US markets on Friday, October 17, 2014, ended on a positive note as the Dow Jones Industrial Average finished at 16,380.41, up 1.63% and the NASDAQ Composite closed at 4,258.44, up 0.97%. The S&P 500 finished the session 1.29% higher at 1,886.76. During the trading session, all the ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 707.88, up 1.61%, with the index advancing 10.21% on YTD basis. Register for your complimentary reports on these five stocks at:
BMRN: 86.93 (+3.02), LXRX: 1.37 (+0.02), AMGN: 162.07 (+1.82), REGN: 382.94 (+5.10), EXEL: 1.76 (+0.02)

Trade-Ideas: Biomarin Pharmaceutical (BMRN) Is Today's "Roof Leaker" Stock
at The Street - Tue Oct 14, 9:13AM CDT
Trade-Ideas LLC identified Biomarin Pharmaceutical (BMRN) as a "roof leaker" (crossing below the 200-day simple moving average on higher than normal relative volume) candidate
BMRN: 86.93 (+3.02)

BioMarin to Host Third Quarter 2014 Financial Results Conference Call and Webcast on Thursday, October 23 at 4:30pm ET
GlobeNewswire - Wed Oct 08, 7:35AM CDT
BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will host a conference call and webcast on Thursday, October 23, at 4:30 p.m. ET to discuss third quarter 2014 financial results and provide a general business update.
BMRN: 86.93 (+3.02)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Strategic Hire: Whisenhunt Joins FlexScreen & RiteScreen

Shaking Up the Window Screens Biz If you've been grinding in the window and door game, you know it's not an industry with a lot of buzz, but here comes a shot of caffeine. FlexScreen and RiteScreen just snagged David Whisenhunt to rev up their sales machine. Who's David Whisenhunt? Well, he's no rookie. With over two decades deep in the fenestration field, Whisenhunt...

AllyGPO Shines as Top Innovator in Health Tech

Innovative Excellence in Healthcare Tech It's not every day you see a specialty group purchasing organization like AllyGPO snagging a spot on Fast Company's esteemed list of Best Workplaces for Innovators. Making it into the top half at number 40 in 2026, it’s a testament to a company really leaning into employee-driven innovation. And, buddy, this ain't just corporate...

Hanover Unveils Skinny Veg® for GLP-1 Dieters

Seems like Hanover Foods is turning heads with their move into the ever-demanding health-conscious market. This family's stepping into the limelight with their new Skinny Veg® line, clearly targeting folks riding the GLP-1 wave. You see, it's not every day that a company that's been around the block since 1924 shakes things up like this. Simplicity is the Name of the...

Webinar Highlights Workforce Skills and AI Tools

The Shift Towards Skills-Based Talent Development The labor market's in a whirl, folks. Employers are scrambling to adapt to rapid changes, chasing after 'skills intelligence' like it's going out of style. On September 24, University of Phoenix, with its band of partners including Jobs for the Future and Skillmore™, will dig into this very topic. This upcoming webinar...

Life Flower Celebrates 16 Years with Dog Adoption Event

A Celebration with Heart Ah, the classic mix of business and community goodwill—that's what Life Flower Dispensary is all about this year. You know, not every business that hits the 16-year mark decides to make it about something bigger than just slashing prices or hyping themselves up. But Life Flower? They're using their anniversary to throw a shindig that's more than...

Mandeville Pests: Health Dangers Lurking at Home

Pest Trouble Brewing in Mandeville: A Health Alert There’s a storm brewing in Mandeville, Louisiana, and it's not the kind you can see rolling in on the horizon. We're talking about those sneaky pests going unnoticed in our homes. Folks, these pests aren't just a nuisance; they're ticking time bombs for public health. Take it from J&J Exterminating, who know a thing or...

VitalCore Pioneers Jail Behavioral Health Expansion

The Big Move in Correctional Healthcare VitalCore Health Strategies has made an impressive move with the opening of a 60-bed Behavioral Health Unit at Shawnee County Jail in Topeka, Kansas. The unit, part of a $21 million expansion completed on August 24, is set to change the landscape for inmates needing mental health and substance use treatment. This isn't just a slap...

Illinois' Legal Tangle: Feds Under Fire?

What a tangled web Illinois lawmakers have woven this time. They've gone and cooked up a pair of laws with a real knack for attracting attention—specifically from the folks over at the National Police Association (NPA). These aren’t your run-of-the-mill rules; they feel more like a blueprint for putting federal officers through the legal wringer and turning courtroom...

Drunk Angel Celebrates First Year in Crystal Jewelry

One Year Down, A Unique Path Forward It's been a year since Drunk Angel jumped into the online jewelry scene, and they're setting themselves apart in their own glittery lane. Imagine starting a brand that's not just about pretty trinkets, but about linking those tiny treasures to timeless traditions. They've got their sights set on blending the deep tales of gemstones...

IDX Expands, Enhances Team Amid 56% H1 Growth

IDX's Aggressive Global Expansion Here's a tip from a trader who’s seen cycles rise and fall: watch the movers who're playing the long game, putting down roots worldwide while making headway in the data game. IDX has clearly mapped out this trajectory as evidenced by its recent grab in the global strategic communications ring. IDX's bustling around like a squirrel...